Why the study?
Does milnacipran improve depression scores and are there blood biomarkers associated with response or adverse effects in patients with major depressive disorder following SSRI failure?
Does milnacipran improve depression scores and are there blood biomarkers associated with response or adverse effects in patients with major depressive disorder following SSRI failure?
Baseline serum levels of IL-6 and IL-8 may serve as biomarkers to identify patients at risk for moderate-to-severe adverse effects when switching to milnacipran after SSRI failure.
Answers are grounded in this paper and cite their sources.
Findings support cautious milnacipran use after SSRI failure; IL-6/IL-8 associations with adverse effects remain hypothesis-generating.
BACKGROUND: We assessed the effect of switching patients with major depressive disorder to milnacipran following an initial selective serotonin reuptake inhibitor treatment failure, and explored potential biomarkers in their blood. METHODS: We conducted a prospective, open-label, 24-week trial. Depression was assessed with the 17-item Hamilton Depression Rating Scale. Patients showing a ≥50% reduction in Hamilton Depression Rating Scale scores from baseline to final visit were considered responders. Regarding adverse effects (AEs), moderate-to-severe AEs were specifically identified as effects that required any medical treatment or that induced treatment withdrawals. We also measured blood levels of various molecules including inflammatory cytokines. RESULTS: Of the 30 participants who enrolled, 17 completed this study. The responder rate was 30% (n=10). Baseline serum levels of interleukin-6 (Z=-2.155; P=0.031) and interleukin-8 (Z=-2.616; P=0.009) were significantly higher when moderate-to-severe AEs were present (n=13 patients with moderate-to-severe AEs). Serum levels of macrophage inflammatory protein-1β showed a significant continuous decrease from the baseline level (Friedman's test: χ (2)=23.9, df=4, P<0.001) only in non-responders. CONCLUSION: These results demonstrate that serum levels of interleukin-6, interleukin-8, and macrophage inflammatory protein-1β as potential blood biomarkers could be utilized to identify the responsiveness of patients to serotonin and norepinephrine reuptake inhibitor like milnacipran, or to identify those patients who may experience AEs strong enough to warrant discontinuation of treatment.
No takes yet. Share an insight, caveat, or question.
Hashimoto et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: